IntelliHep (United Kingdom)
Our team have over 70 years of complementary expertise between them in heparin glycobiology, heparin chemistry, sugar analysis and purification, protein/carbohydrate interactions and screening. Our R&D portfolio spans generation of novel heparin-based compounds for both in-house and collaborative studies, and developing lead candidates for Alzheimers disease and cancer. IntelliHep is exploiting a technology platform to generate novel heparin-based chemical entities, and also pursuing in-house pr
Basic Information
- Category: business
- Website: http://www.intellihep.com/
Documented Facts
- Phone: +4401517954427 (No linked source recorded for this statement.)
- Email: info@intellihep.com (No linked source recorded for this statement.)
Evidence and Sources
- IntelliHep (United Kingdom) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about IntelliHep (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/intellihep-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/intellihep-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/intellihep-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (80/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Our team have over 70 years of complementary expertise between them in heparin glycobiology, heparin chemistry, sugar analysis and purification, protein/carbohydrate interactions and screening. Our R&D portfolio spans generation of novel heparin-based compounds for both in-house and collaborative studies, and developing lead candidates for Alzheimers disease and cancer. IntelliHep is exploiting a technology platform to generate novel heparin-based chemical entities, and also pursuing in-house pr
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.